Global X Genomics & Biotechnology ETF
Find Ratings Reports- Last Ratings Update:02/29/2024
- Price as of 02/29/2024 :$11.98
- Net Assets:$0 Million
- NAV:$12.29
- Premium-2.52%
- Peer Rank:44 of 48
- Investment Rating:E
- Performance:E
- RiskC-
We rate Global X Genomics and Biotechnology at E. Negative factors that influence this rating include a short term portfolio management tenure. The fund may be considered for investors seeking a Sector - Health/Biotechnology strategy.
Total return ranks well below peers over the last three years. The Global X Genomics and Biotechnology has returned an annual rate of -4.99% since inception. More recently, the fund has generated a total return of -17.64% in the last three years, -6.96% in the last year, and 7.90% in the last six months. How does that compare to other equity funds? In the last three years, it has outperformed 4% of them. It has also outpaced 7% of its competitors on a one year basis for the period ending 2/29/2024. On a year to date basis, GNOM has returned 6.33%.
Downside risk has been above average. GNOM has a draw down risk of -64.44%, which is the largest price decline experienced over the last three years. This fund has a three year standard deviation of 30.4%. This fund has experienced excessive volatility in its monthly performance over the last 36 months.
Low expense ratio helps performance. As GNOM is an exchange traded fund, it has no front end or back end load.
The Global X Genomics and Biotechnology is managed by Nam To at Global X Management Company LLC. This fund is one of 69 Global X Management Company LLC exchange-traded funds launched since 2/5/2009 that we track.